Search results
Results from the WOW.Com Content Network
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 10 ] It is also used to treat adults with heart failure and chronic kidney disease .
Legal claims against the pharmaceutical industry have varied widely over the past two decades, including Medicare and Medicaid fraud, off-label promotion, and inadequate manufacturing practices. [ 3 ] [ 4 ] With respect to off-label promotion, specifically, a federal court recognized off-label promotion as a violation of the False Claims Act ...
Search the web. Legal Main; Terms of Service Summary; Terms of Service; Legal Information Privacy Policy. Privacy Policy Highlights
How Trump’s Agenda 47, plus Project 2025, offer clues into possible health-care policy changes. Beth Greenfield. November 14, 2024 at 5:15 AM ... off-label uses of drugs are legal and common ...
treaty power, right to jury trial Watkins v. United States: 354 U.S. 178 (1957) rights of a witness in refusing to answer questions before the House Un-American Activities Committee: Yates v. United States: Free Speech: 354 U.S. 298 (1957) free speech, distinction between expression of opinion and advocacy of action Morey v. Doud: 354 U.S. 457 ...
trial court's erroneous deprivation of a criminal defendant's choice of counsel entitles him to reversal of his conviction Kansas v. Marsh: 548 U.S. 163 (2006) statute allowing the death penalty in cases where the aggravating and mitigating evidence are equal does not violate the Eighth Amendment: Randall v. Sorrell: 548 U.S. 230 (2006)
The slew of cases has alarmed legal experts, patient advocates and former health officials from both parties who say the consequences for the health care system — from drugmakers to nurses to ...